Michael Hageman

Dr. Michael Hageman is the Valentino J. Stella Distinguished Professor in the Department of Pharmaceutical Chemistry at the University of Kansas and Director of the Biopharmaceutical Innovation & Optimization Center. With over 30 years of pharmaceutical industry experience prior to academia, his career spans both industrial innovation and academic research leadership.

• Department: Pharmaceutical Chemistry, University of Kansas
• Lab: Physical Pharmacy and Drug Delivery (P2D2) Lab
• Core Research: Physicochemical characterization, formulation optimization, and bioperformance analysis of drugs and excipients
• Key Techniques: Spray-drying, lyophilization, vacuum evaporation, and molecular dynamics simulations

Dr. Hageman's lab focuses on three main research objectives:

1. Developing tools to study solubilized formulations at physiological interfaces
2. Applying advanced processing capabilities for amorphous material generation
3. Identifying instability mechanisms in solid-state peptide/protein drugs

The P2D2 Lab actively collaborates across disciplines while maintaining close-knit team dynamics. Current graduate researchers include Zahraa Al-Tamimi (intestinal media effects on peptides), Sivani Badrivenkata (protein therapies for underserved populations), Xi Luan (high-concentration protein analysis), Indeewara Munasinghe (molecular synthesis for SCB Core), Benjamin Odei Nyarko (ASD stability), Mengjuan Pang (subcutaneous injection models), Yezan Salamoun (prodrug development), Jack Terry (peritoneal drug delivery), and Anthony Tomlinson (protein-polymer conjugate screening).

Scientific advancements from the lab span:

• Amorphous solid dispersion optimization
• Subcutaneous delivery system modeling
• Protein stability and solubility investigations
• Cyclodextrin formulation applications
• Computational approaches to drug-polymer interactions
• Machine learning in dosage form development